Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Increased copy number alterations (CNAs) indicative of chromosomal instability (CIN) have been associated with poor cancer outcome. Here, we study CNAs as potential biomarkers of bevacizumab (BVZ) response in metastatic colorectal cancer (mCRC). We cluster 409 mCRCs in three subclusters characterized by different degrees of CIN. Tumors belonging to intermediate-to-high instability clusters have improved outcome following chemotherapy plus BVZ versus chemotherapy alone. In contrast, low instability tumors, which amongst others consist of POLE-mutated and microsatellite-instable tumors, derive no further benefit from BVZ. This is confirmed in 81 mCRC tumors from the phase 2 MoMa study involving BVZ. CNA clusters overlap with CRC consensus molecular subtypes (CMS); CMS2/4 xenografts correspond to intermediate-to-high instability clusters and respond to FOLFOX chemotherapy plus mouse avastin (B20), while CMS1/3 xenografts match with low instability clusters and fail to respond. Overall, we identify copy number load as a novel potential predictive biomarker of BVZ combination therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170
Genetic instabilities in human cancers
Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1998) · Nature · doi:10.1038/25292 · Cited by 4,168
Saltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0191 · Cited by 2,229
Wang, K., Li, M., Hadley, D., Liu, R., Glessner, J., Grant, S. F. A., Hakonarson, H., & Bucan, M. (2007) · Genome Research · doi:10.1101/gr.6861907 · Cited by 1,792
REporting recommendations for tumour MARKer prognostic studies (REMARK).
for the Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics, McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602678 · Cited by 1,394
Gao, H., Korn, J. M., Ferretti, S., Monahan, J. E., Wang, Y., Singh, M., Zhang, C., Schnell, C., Yang, G., Zhang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3954 · Cited by 1,393
De Sousa E Melo, F., Wang, X., Jansen, M., Fessler, E., Trinh, A., de Rooij, L. P. M. H., de Jong, J. H., de Boer, O. J., van Leersum, R., Bijlsma, M. F., et al. (2013) · Nature Medicine · doi:10.1038/nm.3174 · Cited by 771
The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets
Medico, E., Russo, M., Picco, G., Cancelliere, C., Valtorta, E., Corti, G., Buscarino, M., Isella, C., Lamba, S., Martinoglio, B., et al. (2015) · Nature Communications · doi:10.1038/ncomms8002 · Cited by 302
Cited by
Precision therapy in RAS mutant colorectal cancer
Dienstmann, R., Connor, K., Byrne, A. T., Fridman, W. H., Lambrechts, D., Sadanandam, A., Trusolino, L., Prehn, J. H. M., Tabernero, J., & Kolch, W. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.12.051 · Cited by 73
Self-citationInvestigation of colorectal cancer in accordance with consensus molecular subtype classification
Sawayama, H., Miyamoto, Y., Ogawa, K., Yoshida, N., & Baba, H. (2020) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12362 · Cited by 60
Genetic Alterations of Metastatic Colorectal Cancer
Testa, U., Castelli, G., & Pelosi, E. (2020) · Biomedicines · doi:10.3390/biomedicines8100414 · Cited by 44
Metadata
- Authors
- Smeets, D., Miller, I. S., O’Connor, D. P., Das, S., Moran, B., Boeckx, B., Gaiser, T., Betge, J., Barat, A., Klinger, R., van Grieken, N. C. T., Cremolini, C., Prenen, H., Mazzone, M., Depreeuw, J., Bacon, O., Fender, B., Brady, J., Hennessy, B. T., McNamara, D. A., Kay, E., Verheul, H. M., Maarten, N., Gallagher, W. M., Murphy, V., Prehn, J. H. M., Koopman, M., Punt, C. J. A., Loupakis, F., Ebert, M. P. A., Ylstra, B., Lambrechts, D., & Byrne, A. T.
- Venue
- Nature Communications
- Published
- 2018-10-05
- Volume
- 9
- Issue
- 1
- Pages
- 4112-4112
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W2894719048
- Cited by
- 80
- References
- 9
- FWCI
- 3.12
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy. https://app.cochat.ai/papers/10.1038/s41467-018-06567-6
- The paper
- Smeets, D., Miller, I. S., O’Connor, D. P., Das, S., Moran, B., Boeckx, B., Gaiser, T., Betge, J., Barat, A., Klinger, R., van Grieken, N. C. T., Cremolini, C., Prenen, H., Mazzone, M., Depreeuw, J., Bacon, O., Fender, B., Brady, J., Hennessy, B. T., . . . Byrne, A. T. (2018). Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy. Nature Communications. https://doi.org/10.1038/s41467-018-06567-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.